Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat Window of Opportunity in Solid Tumors
NCT03471286Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jun 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epacadostat in solid tumor, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Pharmacodynamic effects as measured by changes in biomarkers in pre- and post-dose tumor and blood specimens at 1 year. Started Jun 2019; status: terminated.
02
Drugs
epacadostat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03471286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03471286.